通化東寶(600867.SH):口服小分子GLP-1受體激動劑(THDBH110膠囊)申報臨牀獲得受理
格隆匯8月21日丨通化東寶(600867.SH)公佈,全資子公司東寶紫星(杭州)生物醫藥有限公司於近日取得國家藥品監督管理局藥品審評中心簽發的關於口服小分子GLP-1受體激動劑(THDBH110膠囊)臨牀試驗申請受理通知書。
胰高血糖素樣肽-1受體是當前治療II型糖尿病和肥胖症最受關注的藥物靶標之一。然而現有的GLP-1受體激動劑均為注射類大分子或多肽藥物,用藥依從性具備改善空間。THDBH110分子是一種口服非肽類、小分子GLP-1受體激動劑。臨牀前研究結果顯示,THDBH110膠囊生物利用度高,表現出較好的降糖減重性能。該品種將在降糖、減重以及降低心血管風險等方面為II型糖尿病患者和肥胖患者提供全新的選擇,同時能夠有效提升患者用藥便利性與依從性。截至目前,全球尚無口服小分子GLP-1受體激動劑獲批上市。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.